What are the oral and dental effects of antidepressants. How do different classes of antidepressants impact the risk of dry mouth. Which factors influence the likelihood of experiencing dry mouth as a side effect of antidepressant medication.

The Link Between Antidepressants and Dry Mouth: A Comprehensive Analysis

Antidepressants are widely prescribed medications used to treat various mental health conditions. However, these drugs can come with side effects, one of which is dry mouth, also known as xerostomia. A meta-analysis conducted by researchers at Yale University has shed light on the relationship between second-generation antidepressants and the risk of developing dry mouth.

The study, published in Progress in Neuropsychopharmacology & Biological Psychiatry, analyzed data from 99 double-blind, randomized, placebo-controlled trials involving 20,868 adults. The research aimed to quantify the risk of dry mouth associated with commonly prescribed antidepressant agents and examine the potential implications of medication class, dose, and pharmacodynamics on this side effect.

Comparing SSRI and SNRI Antidepressants: Which Carry a Higher Dry Mouth Risk?

The meta-analysis revealed significant differences in the risk of dry mouth between different classes of antidepressants:

• Selective Serotonin Reuptake Inhibitors (SSRIs): Relative Risk (RR) = 1.65, 95% Confidence Interval (CI): 1.39-1.95
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): RR = 2.24, 95% CI: 1.95-2.58

These findings indicate that SNRIs are associated with a significantly higher risk of dry mouth compared to SSRIs. The test for subgroup differences yielded a χ2 value of 7.6 (df=1, p=0.006), confirming the statistical significance of this difference.

The Impact of Diagnosis on Dry Mouth Risk in SNRI Users

Interestingly, the study found that the risk of dry mouth varied depending on the underlying diagnosis for which SNRIs were prescribed:

• Anxiety disorders: RR = 2.78, 95% CI: 2.29-3.38
• Depressive disorders: RR = 1.80, 95% CI: 1.48-2.18

The test for subgroup differences (χ2 = 9.63, df=1, p=0.002) confirmed that patients with anxiety disorders were at a significantly higher risk of experiencing dry mouth when taking SNRIs compared to those with depression.

Receptor Affinity and Its Role in Dry Mouth Side Effects

The researchers also investigated the relationship between an antidepressant’s receptor affinity profile and the risk of dry mouth. Their findings revealed:

• Decreased affinity for Alpha-1 receptors: PE = 0.18, 95% CI: 0.07-0.28
• Decreased affinity for Alpha-2 receptors: PE = 0.49, 95% CI: 0.22-0.75
• Decreased affinity for SERT (serotonin transporter): PE = 0.07, 95% CI: 0.01-0.14

These results suggest that antidepressants with lower affinity for these receptors are associated with an increased risk of dry mouth. This information could be valuable for healthcare providers when selecting appropriate medications for patients who may be more susceptible to this side effect.

Implications for Patient Care and Medication Management

Understanding the varying risks of dry mouth associated with different antidepressant classes and individual medications is crucial for healthcare providers and patients alike. This knowledge can inform treatment decisions and help in managing potential side effects.

For patients experiencing dry mouth as a side effect of their antidepressant medication, several strategies can be employed:

• Staying hydrated by drinking water regularly
• Using sugar-free gum or lozenges to stimulate saliva production
• Avoiding caffeine, alcohol, and tobacco, which can exacerbate dry mouth
• Discussing potential medication adjustments with a healthcare provider

The Importance of Oral Health Monitoring in Antidepressant Users

Given the increased risk of dry mouth associated with antidepressant use, it’s essential for patients to pay close attention to their oral health. Dry mouth can lead to various dental problems, including:

• Increased risk of tooth decay
• Gum disease
• Oral infections
• Difficulty speaking and swallowing

Regular dental check-ups and maintaining good oral hygiene practices are particularly important for individuals taking antidepressants. Dentists may recommend additional preventive measures or treatments to mitigate the effects of dry mouth on oral health.

Future Research Directions in Antidepressant-Induced Dry Mouth

While this meta-analysis provides valuable insights into the relationship between antidepressants and dry mouth, several areas warrant further investigation:

• Long-term effects of antidepressant-induced dry mouth on oral health
• Development of antidepressants with lower risks of dry mouth
• Personalized medicine approaches to predict individual susceptibility to this side effect
• Effectiveness of interventions to manage dry mouth in antidepressant users

Continued research in these areas could lead to improved treatment options and better quality of life for individuals requiring antidepressant therapy.

Balancing Mental Health Treatment with Oral Health Concerns

The findings of this meta-analysis highlight the need for a balanced approach when prescribing antidepressants. While these medications are often essential for managing mental health conditions, the potential side effects, including dry mouth, should be carefully considered and monitored.

Healthcare providers should engage in open discussions with patients about the risks and benefits of different antidepressant options. This dialogue can help in selecting the most appropriate medication while also preparing patients for potential side effects and providing strategies to manage them effectively.

Collaborative Care: The Role of Mental Health Professionals and Dentists

To ensure comprehensive care for patients taking antidepressants, collaboration between mental health professionals and dentists is crucial. This interdisciplinary approach can help in:

• Early detection of oral health issues related to dry mouth
• Implementing preventive measures to protect dental health
• Adjusting medications or treatment plans when necessary
• Providing holistic care that addresses both mental and oral health needs

By fostering communication between these healthcare providers, patients can receive more integrated and effective care, minimizing the impact of side effects on their overall well-being.

Patient Education: Empowering Individuals to Manage Their Health

Educating patients about the potential side effects of antidepressants, including dry mouth, is essential. This knowledge empowers individuals to:

• Recognize symptoms early and seek appropriate care
• Implement self-care strategies to manage dry mouth
• Make informed decisions about their treatment in consultation with healthcare providers
• Advocate for their health needs and concerns

Healthcare providers should provide clear, accessible information about dry mouth and other potential side effects when prescribing antidepressants. This can include written materials, online resources, and follow-up discussions to address any questions or concerns that may arise during treatment.

Exploring Alternative Treatments and Complementary Approaches

For patients who are particularly susceptible to dry mouth or find it significantly impacting their quality of life, exploring alternative treatment options may be warranted. This could include:

• Different classes of antidepressants with lower risks of dry mouth
• Non-pharmacological interventions for mental health, such as psychotherapy
• Complementary approaches to manage both mental health and dry mouth symptoms

It’s important to note that any changes to medication or treatment plans should be made under the guidance of a qualified healthcare professional. Abruptly stopping or changing antidepressant medications can lead to withdrawal symptoms and potentially worsen mental health conditions.

Advancing Pharmacological Research for Improved Medications

The findings of this meta-analysis underscore the need for continued research and development in the field of psychopharmacology. Future directions for research may include:

• Developing antidepressants with more selective receptor profiles to minimize side effects
• Investigating the potential of combination therapies to reduce the risk of dry mouth
• Exploring novel drug delivery methods that could mitigate oral side effects
• Conducting long-term studies to better understand the cumulative effects of antidepressant use on oral health

By advancing our understanding of the mechanisms underlying antidepressant-induced dry mouth, researchers may be able to develop more targeted and effective treatments with fewer side effects.

The Role of Technology in Monitoring and Managing Side Effects

As healthcare continues to evolve, technology may play an increasingly important role in monitoring and managing side effects of antidepressants, including dry mouth. Potential applications include:

• Smartphone apps for tracking symptoms and medication adherence
• Telemedicine platforms for remote consultations with healthcare providers
• Wearable devices to monitor oral health parameters
• Artificial intelligence-driven systems for early detection of side effects

These technological advancements could help in providing more personalized and timely care for individuals taking antidepressants, potentially improving outcomes and quality of life.

The Economic Impact of Antidepressant-Induced Dry Mouth

While not directly addressed in the meta-analysis, it’s important to consider the potential economic implications of antidepressant-induced dry mouth. These may include:

• Increased dental care costs due to higher risk of oral health problems
• Productivity losses associated with managing side effects
• Additional healthcare expenditures for treating complications of dry mouth
• Costs related to switching medications or exploring alternative treatments

Future research examining the economic burden of this side effect could provide valuable insights for healthcare policy and resource allocation.

Conclusion

The meta-analysis conducted by Cappetta et al. provides important insights into the relationship between antidepressants and the risk of dry mouth. By understanding the varying risks associated with different medication classes and individual patient factors, healthcare providers can make more informed decisions when prescribing antidepressants.

Patients, in turn, can be better prepared to manage potential side effects and maintain their oral health while receiving necessary mental health treatment. As research in this area continues to advance, we can hope for the development of more targeted therapies with improved side effect profiles, ultimately leading to better outcomes for individuals with mental health conditions.

Meta-analysis: Risk of dry mouth with second generation antidepressants

Review

. 2018 Jun 8;84(Pt A):282-293.

doi: 10.1016/j.pnpbp.2017.12.012.

Epub 2017 Dec 20.

Kiley Cappetta 
¹
, Chad Beyer 
²
, Jessica A Johnson 
²
, Michael H Bloch 
³

Affiliations

Affiliations

• ¹ Department of Psychiatry of Yale University, New Haven, CT, United States.
• ² Yale Child Study Center, New Haven, CT, United States.
• ³ Yale Child Study Center, New Haven, CT, United States; Department of Psychiatry of Yale University, New Haven, CT, United States. Electronic address: [email protected].

• PMID:

  29274375

• DOI:

  10.1016/j.pnpbp.2017.12.012

Review

Kiley Cappetta et al.

Prog Neuropsychopharmacol Biol Psychiatry.

2018.

. 2018 Jun 8;84(Pt A):282-293.

doi: 10.1016/j.pnpbp.2017.12.012.

Epub 2017 Dec 20.

Authors

Kiley Cappetta 
¹
, Chad Beyer 
²
, Jessica A Johnson 
²
, Michael H Bloch 
³

Affiliations

• ¹ Department of Psychiatry of Yale University, New Haven, CT, United States.
• ² Yale Child Study Center, New Haven, CT, United States.
• ³ Yale Child Study Center, New Haven, CT, United States; Department of Psychiatry of Yale University, New Haven, CT, United States. Electronic address: [email protected].

• PMID:

  29274375

• DOI:

  10.1016/j.pnpbp.2017.12.012

Abstract

Objective:

The goal of this meta-analysis was to quantify the risk of dry mouth associated with commonly prescribed antidepressant agents and examine the potential implications of medication class, dose, and pharmacodynamics and dose on risk of treatment-induced dry mouth.

Data sources and study selection:

A PubMed search was conducted to identify double-blind, randomized, placebo-controlled trials examining the efficacy and tolerability of second generation antidepressant medications for adults with depressive disorders, anxiety disorders, and OCD.

Data extraction:

A random-effects meta-analysis was used to quantify the pooled risk ratio of treatment-emergent dry mouth with second generation antidepressants compared to placebo. Stratified subgroup analysis and meta-regression was utilized to further examine the effects antidepressant agent, class, dosage, indication, and receptor affinity profile on the measured risk of dry mouth.

Results:

99 trials involving 20,868 adults. SNRIs (Relative Risk (RR)=2.24, 95% Confidence Interval (CI): 1. 95-2.58, z=11.2, p<0.001) were associated with a significantly greater risk of dry mouth (test for subgroup differences χ²=7.6, df=1; p=0.006) compared to placebo than SSRIs (RR=1.65, 95% CI: 1.39-1.95, z=5.8, p<0.001). There was a significant difference found in the risk of dry mouth between diagnostic indications within the SNRI class (test for subgroup differences χ²=9.63, df=1; p=0.002). Anxiety diagnoses (RR=2.78, 95% CI: 2.29-3.38, z=10.32, p<0.001) were associated with a greater risk of dry mouth compared to depression (RR=1.80, 95% CI: 1.48-2.18, z=5.85, p<0.001). Decreased affinity for Alpha-1 (PE=0.18, 95% CI: 0.07-0.28, z=3.26, p=0.001) and Alpha-2 (PE=0.49, 95% CI: 0.22-0.75, z=3.64, p<0.001) receptors and SERT (PE=0.07, 95% CI: 0.01-0.14, z=2.10, p<0.05) was significantly associated with increased risk of dry mouth.

Conclusions:

The current meta-analysis suggests that SSRIs, SNRIs, and atypical antidepressants are all associated with varying degrees of increased risk of dry mouth. SNRIs were associated with a significantly greater risk of dry mouth compared to SSRIs.

Keywords:

Dry mouth; Meta-analysis; Second generation antidepressants; Serotonin uptake inhibitors; Xerostomia.

Copyright © 2017 Elsevier Inc. All rights reserved.

Similar articles

• Meta-analysis: Second generation antidepressants and headache.

  Telang S, Walton C, Olten B, Bloch MH.

  Telang S, et al.
  J Affect Disord. 2018 Aug 15;236:60-68. doi: 10.1016/j.jad.2018.04.047. Epub 2018 Apr 9.
  J Affect Disord. 2018.

  PMID: 29715610

  Review.

• Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants.

  Beyer C, Cappetta K, Johnson JA, Bloch MH.

  Beyer C, et al.
  Depress Anxiety. 2017 Dec;34(12):1134-1146. doi: 10.1002/da.22680. Epub 2017 Sep 7.
  Depress Anxiety. 2017.

  PMID: 28881483

• Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.

  Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA.

  Bridge JA, et al.
  JAMA. 2007 Apr 18;297(15):1683-96. doi: 10.1001/jama.297.15.1683.
  JAMA. 2007.

  PMID: 17440145

• Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis.

  Mills JA, Strawn JR.

  Mills JA, et al.
  J Am Acad Child Adolesc Psychiatry. 2020 Nov;59(11):1240-1251. doi: 10.1016/j. jaac.2019.10.013. Epub 2019 Nov 1.
  J Am Acad Child Adolesc Psychiatry. 2020.

  PMID: 31682918
  Free PMC article.

• Tolerability and safety: essentials in antidepressant pharmacotherapy.

  Lader MH.

  Lader MH.
  J Clin Psychiatry. 1996;57 Suppl 2:39-44.
  J Clin Psychiatry. 1996.

  PMID: 8626362

  Review.

See all similar articles

Cited by

• Major depression-related factor NEGR1 controls salivary secretion in mouse submandibular glands.

  Lee J, Kim S, Lee B, Kim YB, Kim KH, Chung G, Lee SJ, Lee S, Sun W, Park HK, Choi SY.

  Lee J, et al.
  iScience. 2023 Apr 26;26(5):106773. doi: 10.1016/j.isci.2023.106773. eCollection 2023 May 19.
  iScience. 2023.

  PMID: 37216094
  Free PMC article.

• Dry mouth effects from drugs used for depression, anxiety, schizophrenia and bipolar mood disorder in adults: systematic review.

  Teoh CXW, Thng M, Lau S, Taing MW, Chaw SY, Siskind D, Kisely S.

  Teoh CXW, et al.
  BJPsych Open. 2023 Mar 20;9(2):e53. doi: 10.1192/bjo.2023.15.
  BJPsych Open. 2023.

  PMID: 36938801
  Free PMC article.

  Review.

• Progress in salivary glands: Endocrine glands with immune functions.

  Shang YF, Shen YY, Zhang MC, Lv MC, Wang TY, Chen XQ, Lin J.

  Shang YF, et al.
  Front Endocrinol (Lausanne). 2023 Feb 3;14:1061235. doi: 10.3389/fendo.2023.1061235. eCollection 2023.
  Front Endocrinol (Lausanne). 2023.

  PMID: 36817607
  Free PMC article.

  Review.

• Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

  Chaurasiya ND, Leon F, Muhammad I, Tekwani BL.

  Chaurasiya ND, et al.
  Molecules. 2022 Jul 4;27(13):4297. doi: 10.3390/molecules27134297.
  Molecules. 2022.

  PMID: 35807542
  Free PMC article.

  Review.

• Salivary Gland Dysfunction Secondary to Cancer Treatment.

  Vistoso Monreal A, Polonsky G, Shiboski C, Sankar V, Villa A.

  Vistoso Monreal A, et al.
  Front Oral Health. 2022 Jun 9;3:907778. doi: 10.3389/froh.2022.907778. eCollection 2022.
  Front Oral Health. 2022.

  PMID: 35757443
  Free PMC article.

  Review.

See all “Cited by” articles

Publication types

MeSH terms

Substances

Are Your Anxiety Medications Causing Dry Mouth?

Are Your Anxiety Medications Causing Dry Mouth?Skip to main content< Back to the article list

Do you suffer from anxiety? If you’re one of millions of Americans taking prescription medications to control either acute or chronic anxiety, you may also be experiencing unwanted side effects, such as Dry Mouth. In fact, it is the most commonly reported side effect of psychiatric medications, with an average of 40% of patients complaining of Dry Mouth.

Prescription medication can be an important ally in treating anxiety. Unfortunately, any medication that’s taken systemically (i.e. swallowed and absorbed into the system) can affect your whole body – not just the part it’s meant for. Antianxiety medications are no exception. As someone who’s already anxious, the last thing you want to worry about is Dry Mouth symptoms like bad breath and difficulty speaking.

There are four major classes of medications that can be prescribed to treat anxiety – many of them antidepressants, which are known to have Dry Mouth as a potential side effect. Each class works slightly differently.

Selective serotonin reuptake inhibitors (SSRIs)

SSRIs are antidepressants and mood enhancers, working by enabling more serotonin to be available to the brain. They are commonly prescribed for generalized anxiety. SSRIs can, however, still cause Dry Mouth. Anticholinergics are medications that would block actions of acetylcholine, which is a type of neurotransmitter. This would result in blockage of involuntary muscle movements and various bodily functions. An example of such are typically related to the production of saliva, digestion, urination or movements. SSRIs you might recognize include citalopram, fluoxetine and sertraline.

Serotonin-norepinephrine reuptake inhibitors (SNRIs)

SNRIs work in a similar fashion to SSRIs, with an increase in both serotonin and norepinephrine, in the brain. They may be prescribed as a longer-term treatment for anxiety and have been shown to cause Dry Mouth. SNRIs that are frequently prescribed for anxiety include venlafaxine, desvenlafaxine and duloxetine.

Tricyclic antidepressants (TCAs)

TCAs are the oldest category of antidepressants, being the first kind to be developed, they are potent and closely linked to Dry Mouth . Perhaps luckily, they are less commonly prescribed for anxiety.

Benzodiazepines and antihistamines

These drugs have a relaxing effect and are prescribed for short-term treatment or longer-term management depending upon the circumstances, severity of symptoms or other medical conditions. Benzodiazepines include medications such as diazepam and alprazolam; antihistamines prescribed for anxiety include, but not limited to, hydroxyzine. They are all known to cause Dry Mouth.

Beta blockers

Typically prescribed for heart conditions, beta blockers help stop the body’s ‘fight or flight’ response. This is characterized by a rapid heartbeat, pounding chest and cold sweat and will be familiar to those who suffer from panic attacks. Beta blockers are sometimes prescribed for people prone to social anxiety or panic attacks, because they stop the physical symptoms. Unfortunately, beta blockers, such as propranolol, are also one of the groups of medications most closely linked to Dry Mouth.

If you think your antianxiety or any medication may be causing Dry Mouth symptoms, have a word with your doctor. You should also refrain from smoking or drinking alcohol, which can make Dry Mouth worse. Finally, find some relief from Dry Mouth symptoms with the Biotène Oral Rinse, Oralbalance Gel, and Moisturizing Spray products.

Related articles

HOW TO REDUCE HYPOSAILIVATION

The unpleasant sensation of dry mouth is said to begin when there is a 45 percent or more decrease in normal saliva production. Also, a feeling of dry mouth is possible with a change in the normal composition of saliva. However, this condition is not always the main one because other symptoms found in this patient population are often perceived as more important.

Dry mouth can be manifested by dysphagia (impaired swallowing), oral discomfort, loss of taste and prolonged chewing of food, and can also have a significant negative impact on quality of life. Hyposalivation also causes difficulty speaking, and mouth discomfort may be exacerbated by denture wearers. Patients with dry mouth may develop lesions and cracks in the oral mucosa, and bad breath can be another unpleasant feature.

Xerostomia can lead to malnutrition and even reduced social interaction. Patients with dry mouth also have a higher risk of developing caries. Decreased saliva production predisposes patients to an overgrowth of Candida albicans, which causes oral thrush (candidiasis). In patients who have received radiation therapy to the head and neck, widespread caries is detected several weeks after treatment.

Approximately 90 percent of saliva is produced by the major salivary glands, the parotid, submandibular, and sublingual glands. The remaining 10 percent is secreted by hundreds of minor salivary glands under the oral mucosa. It is believed that in healthy people saliva is about one liter per day.

Causes of xerostomia
Quite often, drug treatment can be the main cause of dry mouth or a factor contributing to the development of xerostomia: reducing the secretion of saliva (hyposalivation) or changing the composition of saliva.

Over 500 drugs are believed to cause dry mouth, including cancer chemotherapy. The risk of xerostomia increases with the amount of medication taken by the patient.

Listed below are some of the more common medications that cause dry mouth. For example, opioids can cause dry mouth, as can tricyclic antidepressants, antihistamines, and diuretics. Drugs with antimuscarinic properties can significantly reduce saliva production. Nasal congestion and subsequent mouth breathing can lead to dryness of the mouth, lips, and throat.

Dry mouth preparations:

• Drugs used to treat parkinson’s disease
• Benzodiazepines
• Bronchodilators (ipratropium bromide)
• Serotonin reuptake inhibitor antidepressants (citalopram, fluoxetine, sertraline)
• Tricyclic antidepressants (amitriptyline)
• Atropine
• Medicines for irritable bowel syndrome
• Drugs for the treatment of frequent urination (oxybutynin, tolterodine, solifenacin)
• Diuretics (furosemide, thiazide diuretics)
• Antihypertensive drugs (captopril, enalapril, clonidine, lisinopril)
• Anticonvulsants (carbamazepine)
• Antihistamines

Fluid intake is important, as is the psychological state of the patient. Anxiety and chronic stress can be major contributors to dry mouth due to autonomic hyperactivity. Caffeine and nicotine intake can also contribute to dry mouth.

Xerostomia is common in cancer patients. Approximately 30 percent of cancer patients have problems with dry mouth, which worsens as the disease progresses. Radiation therapy to the mouth, head, or neck can cause severe xerostomia and hyposalivation. Salivary gland tissue is very sensitive to ionizing radiation and a dose > 30 Gy can irreversibly alter salivary secretion depending on the location of the salivary glands relative to the radiation therapy field.

Dry mouth can be caused by a variety of conditions and is not necessarily the result of an existing cancer or treatment regimen. There is an association of xerostomia with aging, with prevalence tending to increase with age, accounting for approximately 30 percent of the population over 65 years of age. Diabetes can cause dry mouth, as can other systemic conditions such as thyroid disease, rheumatoid arthritis, and Sjögren’s syndrome. Sarcoidosis and hemochromatosis are examples of rarer conditions that can lead to destruction of the salivary glands. It is also believed that the syndrome of transplant rejection (eg, kidney) contributes to the development of symptoms of dry mouth.

Therapy and symptomatic treatment xerostomia
First of all, the reversible causes of xerostomia should be targeted. Talk to your doctor about your medications to determine if you can stop taking them or reduce your dosage. Alternative drugs may have less antimuscarinic properties. Any associated infections such as candidiasis should be treated with antifungal tablets, suspensions or gels (miconazole).
Patients with mouth breathing may be given a short course of topical nasal decongestants (xylometazoline, oxymetazoline). As mentioned above, dry mouth can be caused by excessive anxiety and / or chronic stress, so this possible cause should also be eliminated if possible.

Practical symptomatic treatment options can help. Frequent water intake throughout the day may be sufficient for some patients. Holding ice cubes in your mouth to provide some moisture may also relieve symptoms. Other measures include sucking on pineapple slices, frequent sips of cold orange juice or semi-frozen fruit juice, or chewing sugar-free gum. Patients may find it helpful to use olive oil, and some products containing olive oil have been shown to be helpful in the symptomatic treatment of dry mouth.

Saliva substitutes are widely used for patients with xerostomia. Various formulations exist, including rinses, aerosols, chewing gums, and dentifrices, and they may also play a role in stimulating salivary gland secretion. It is possible to use saliva substitutes before meals. Also, preparations containing hyaluronic acid are used to moisturize the oral cavity – sometimes in combination with amino acids.

In particular, VITA-GIAL spray (sodium hyaluronate), can be used to periodically moisturize the oral cavity throughout the day. Hyaluronic acid not only moisturizes the oral cavity, but also restores the damaged mucosa, and also envelops it – preventing the penetration of bacteria through microcracks.

VITA-HYAL gel has a longer duration of action than an aerosol and is usually applied to the oral mucosa in the morning and before bedtime. Sometimes it is necessary to apply it additionally – after a meal.

Good oral hygiene is also essential. Some patients may be recommended treatment with pilocarpine, which stimulates the secretion of the salivary glands, but it has a lot of side effects.

You can buy “Vita-Gial” in our online store rivierabiotech.store

Second generation antidepressants for winter depression

Relevance

Seasonal affective disorder (winter depression) is a type of depression that appears in autumn and persists until spring. Its symptoms are similar to those of ordinary depression, except that patients suffering from such depression tend to experience extreme fatigue and increased appetite. The disorder is more common in countries with a lack of light hours during the winter season. One of the main treatments for all types of depression, including winter depression, are second-generation antidepressants (A-II), such as selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SSRIs). It is not known how well these medications work and how they compare to each other or to other treatments for winter depression, such as light therapy.

Results

We found three clinical trials with a total of 204 participants that tested A-II (fluoxetine) alone versus placebo (dummy) or light therapy. In one clinical trial (68 participants), fluoxetine was compared with placebo, although participants who received fluoxetine responded more frequently to treatment, there was not enough data to say with certainty that there was any difference from placebo. Approximately the same number of participants in both groups experienced side effects.

We found two clinical trials with a total of 136 participants comparing fluoxetine and light therapy. When we combined the results of these two trials, we found that both treatments were similar in their effects, with about 66 out of 100 people improving in both the fluoxetine and light therapy groups. The number of participants with side effects was also about the same in both the fluoxetine treatment group and the light therapy group.

We found five additional studies that provided safety data for A-II in the treatment of winter depression. They reported side effects A-II: bupropion, fluoxetine, escitalopram, duloxetine, nefazodone, and reboxetine. We were not able to directly compare these medications, but we can note that between 0% and 25% of people dropped out early due to side effects, and the most common side effects were nausea, diarrhea, sleep disturbances, decreased libido, dryness. in the mouth and anxiety. We were unable to compare the incidence of side effects in people taking A-II compared to placebo, which means our confidence in the side effect information is limited.